The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-10-07 03:44
摘要：
OTUB1 has been identified as a critical factor in gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through the stabilization of DHODH mRNA. The study demonstrates that targeting OTUB1 can improve the efficacy of gemcitabine treatment, suggesting a promising therapeutic strategy for patients with pancreatic cancer. The findings indicate the potential for early-stage investment in therapies that target metabolic pathways in oncology.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
OTUB1 was found to be aberrantly expressed in pancreatic cancer and correlated with poor patient survival.
OTUB1 knockdown increased gemcitabine efficacy by inhibiting pyrimidine metabolism.
A small-molecule OTUB1 inhibitor combined with gemcitabine treatment synergistically inhibited tumor growth.
真实性检查
否
AI评分总结
OTUB1 has been identified as a critical factor in gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through the stabilization of DHODH mRNA. The study demonstrates that targeting OTUB1 can improve the efficacy of gemcitabine treatment, suggesting a promising therapeutic strategy for patients with pancreatic cancer. The findings indicate the potential for early-stage investment in therapies that target metabolic pathways in oncology.